Search
Clinician Ordering Portal
Empowering people, informing care decisions.
At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
About UsClinical focus areas
Our broad portfolio of innovative tests focuses on answering critical clinical questions. From individualized risk of melanoma metastasis to customized medication profiles for mental health conditions, our tests are designed to deliver personalized information that better informs care decisions.
Dermatology
Gastroenterology
Mental Health
Ophthalmology
Our tests
Cutaneous Melanoma
Make more confident, more accurate treatment plan decisions for sentinel lymph node biopsy guidance as well as surveillance and therapeutic interventions.
Make more confident, more accurate diagnostic decisions with genomic insight for melanocytic lesions.
Cutaneous Squamous Cell Carcinoma (SCC)
Make more confident, more accurate treatment plan decisions for surveillance and therapeutic interventions.
Barrett’s Esophagus
Go beyond tissue morphology to predict a patient’s individualized risk of progression to esophageal cancer in Barrett’s esophagus.
Mental Health
Comprehensive pharmacogenomic (PGx) testing that guides personalized mental health medication selection, tailored to each patient's unique profile.
.svg)
Uveal Melanoma
Make more informed, risk-aligned treatment plan decisions based on comprehensive molecular profiling.
Featured spotlights
-
New independent meta-analysis supporting 31-GEP
This review examined the 31-gene expression profile (31-GEP) test, which analyzes the activity of 31 genes in melanoma tumors to predict the risk of metastasis. Data from multiple studies was systematically reviewed and analyzed to assess the 31-GEP test’s efficacy in predicting melanoma patient outcomes. Our findings suggest that the 31-GEP test may improve risk prediction when used alongside standard clinical and pathological assessments. By using 31-GEP, physicians may be better able to make more informed decisions about treatment and follow-up care, potentially improving outcomes for melanoma patients.
-
Second independent study confirms the ability of DecisionDx-SCC to predict likelihood of benefit from adjuvant radiation therapy in patients with high-risk cutaneous squamous cell carcinoma
-
Explore on-demand MyPath Melanoma case study webinars
Listen to multiple clinicians discuss how gene expression profile testing can provide guidance for difficult-to-diagnose lesions and improve patient management.
-
Largest prospective study to date of patients with uveal melanoma further supports performance of DecisionDx-UM for metastatic risk stratification and highlights PRAME as a valuable adjunct biomarker for further risk refinement when considered in conjunction with a DecisionDx-UM result
-
TissueCypher Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus
-
Pharmacogenomic characteristics and IDgenetix-guided medication management for older adults with depression and anxiety
Poster presented at the annual American Association for Geriatric Psychiatry conference in Atlanta, GA on March 15, 2024.
Relentless pursuit of the best outcomes
At Castle, we combine innovation, advanced technologies and relevant real-world evidence to address critical unmet clinical needs and improve health outcomes.
The validity and utility of Castle’s innovative tests has been demonstrated in more than 150 peer-reviewed publications, and more than 300,000 test reports have been delivered to clinicians since 2008 to guide improved disease management decisions for patients.
The latest
News
Press Release
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
Press Release
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press Release
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by ...
We are transforming disease management. Join in the transformation.
Every employee at Castle has an impact on patient care. If you are interested in making a difference in the lives of patients while doing something that inspires you, find out what exciting opportunities are available within our team.
